Edition:
United Kingdom

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

5.75USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$5.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,327
52-wk High
$21.59
52-wk Low
$5.52

Latest Key Developments (Source: Significant Developments)

Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​
Thursday, 15 Mar 2018 

March 15 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS.REMAINS ON TRACK TO REPORT TOP-LINE RESULTS FROM STUDY IN Q2 OF 2018.QTRLY LOSS PER SHARE $0.63‍​.Q4 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.  Full Article

Gemphire Announces Pricing Of $22 Mln Public Offering Of Common Stock
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE ANNOUNCES PRICING OF $22 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.14 MILLION COMMON SHARES PRICED AT $7.00PER SHARE.  Full Article

Gemphire Announces Proposed Public Offering Of Common Stock
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GEMPHIRE THERAPEUTICS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF CO'S COMMON STOCK​.  Full Article

Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical Trial
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS ANNOUNCES INITIATION OF ITS FIRST NASH PROOF-OF-CONCEPT CLINICAL TRIAL AND ITS DIFFERENTIATED NASH PROGRAM.GEMPHIRE THERAPEUTICS INC - NASH PROGRAM EXPECTED TO BE PHASE 2B READY BY YEAR-END 2018.GEMPHIRE THERAPEUTICS INC - PLANS TO LAUNCH A SECOND PHASE 2A PROOF-OF-CONCEPT TRIAL IN NASH EARLY IN 2018.  Full Article

Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Gemphire Therapeutics Inc :Gemphire Therapeutics Inc qtrly loss per share $0.82‍​.  Full Article

Gemphire announces plans to advance gemcabene into phase 3 clinical development
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces plans to advance gemcabene into phase 3 clinical development.Gemphire Therapeutics Inc - ‍End of phase 2 meetings planned for early 2018​.Says gemcabene successfully achieved primary endpoint in two recently completed phase 2B studies.Gemphire Therapeutics - Results from all 20 clinical studies in 956 patients were exposed to gemcabene have demonstrated gemcabene is well tolerated and safe​.Gemphire-New analysis shows 600 mg of gemcabene reduced ldl-c by 21% in hypercholesterolemic patients, by 25% in mixed dyslipidemic patients in trials.Gemphire - Also plans to develop gemcabene as monotherapy or as add-on therapy to diet and other lipid lowering therapies for treatment of SHTG.  Full Article

Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​
Friday, 1 Sep 2017 

Sept 1 (Reuters) - Gemphire Therapeutics Inc :Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​.  Full Article

Gemphire Therapeutics Inc posts Q2 net loss $0.99/shr
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces second quarter 2017 financial results and provides corporate update.Gemphire Therapeutics Inc - qtrly net loss per share$ 0.99.Gemphire Therapeutics -‍ believes existing cash is sufficient to fund operations through completion of planned nash clinical trial anticipated in H2 2018.Gemphire Therapeutics - also ‍believes existing cash is sufficient to fund operations through completion of remaining dyslipidemia trial​.  Full Article

Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Gemphire Therapeutics Inc :Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients.Gemcabene met primary endpoint and demonstrated a statistically significant lowering in LDL-C.There were no serious adverse events in study.Three subjects discontinued from study, 1 from Gemcabene and 2 from placebo groups.Gemphire Therapeutics - will perform additional analyses to thoroughly evaluate results of trial, once additional analyses complete, will provide update.  Full Article

Gemphire enters into $15 mln term loan agreement with Silicon Valley Bank
Tuesday, 25 Jul 2017 

July 25 (Reuters) - Gemphire Therapeutics Inc :Gemphire enters into $15 million term loan agreement with silicon valley bank.Gemphire therapeutics inc - ‍immediately drew $10 million upon execution of loan agreement on july 24, 2017​.Gemphire therapeutics inc - ‍term loan will mature on february 1, 2021​.  Full Article

BRIEF-Gemphire Therapeutics Reports Qtrly Loss Per Share $0.63‍​

* GEMPHIRE THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS